
Sign up to save your podcasts
Or


Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?
Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.
Presented by Leanna Byrne and produced by Lexy O'Connor
(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)
By BBC World Service4.4
488488 ratings
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?
Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.
Presented by Leanna Byrne and produced by Lexy O'Connor
(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)

7,732 Listeners

4,185 Listeners

1,037 Listeners

283 Listeners

432 Listeners

5,518 Listeners

1,810 Listeners

366 Listeners

958 Listeners

739 Listeners

53 Listeners

248 Listeners

375 Listeners

233 Listeners

666 Listeners

225 Listeners

2,530 Listeners

327 Listeners

3,168 Listeners

64 Listeners

846 Listeners

1,001 Listeners

499 Listeners

112 Listeners

612 Listeners

280 Listeners

276 Listeners

67 Listeners

83 Listeners

1 Listeners